Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Four Stocks, One Big Bet: Sosin’s Carvana Call Delivers 41% Return Stephen Taub Private Equity’s Fundraising Demands Far Outstrip Supply Michelle Celarier Why Bitcoin's Relationship with Equities Has Changed Sponsored by CME Group